Assenagon Asset Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Assenagon Asset Management’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$59.6M	Sell	947,495 -332,699	-26%	-$21.3M	0.07%	204
2026 Q1	$89.8M	Buy	1,280,194 +152,464	+14%	+$10.7M	0.14%	130
2025 Q4	$92.3M	Sell	1,127,730 -120,224	-10%	-$8.98M	0.13%	132
2025 Q3	$74.2M	Buy	1,247,954 +250,367	+25%	+$12.3M	0.1%	167
2025 Q2	$40.4M	Sell	997,587 -127,718	-11%	-$5.75M	0.06%	244
2025 Q1	$57.8M	Sell	1,125,305 -21,507	-2%	-$1.06M	0.1%	185
2024 Q4	$63.5M	Buy	1,146,812 +5,565	+0.5%	+$253K	0.1%	169
2024 Q3	$37.5M	Buy	1,141,247 +77,825	+7%	+$2.19M	0.07%	216
2024 Q2	$28.9M	Buy	+1,063,422	New	+$35.8M	0.06%	223
2023 Q3	–	Sell	-146,194	Closed	-$2.64M	–	1469
2023 Q2	$2.64M	Hold	146,194	–	–	0.01%	672
2023 Q1	$1.84M	Sell	146,194 -37,014	-20%	-$541K	0.01%	864
2022 Q4	$2.69M	Sell	183,208 -19,217	-9%	-$318K	0.01%	713
2022 Q3	$3.47M	Sell	202,425 -159,316	-44%	-$2.53M	0.01%	564
2022 Q2	$5.28M	Buy	+361,741	New	+$5.43M	0.02%	528

Other funds holding TARS

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

EOJOAM

E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

1IA

1620 Investment Advisors Plymouth, Massachusetts $161M AUM 30.15% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

Assenagon Asset Management's TARS Position: Q2 2026 in Review

Assenagon Asset Management reduced its Tarsus Pharmaceuticals (TARS) stake by 26% in Q2 2026, selling an estimated $21.3M and leaving 947,495 shares worth $59.6M. The position accounts for 0.07% of the portfolio, ranked #204.

Assenagon Asset Management first reported a position in TARS in Q2 2022 and has held it in 14 quarters since. The position peaked at $92.3M in Q4 2025. 15 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Assenagon Asset Management held 947,495 shares of Tarsus Pharmaceuticals worth $59.6M as of Q2 2026.
Assenagon Asset Management sold 332,699 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $21.3M.
Tarsus Pharmaceuticals made up 0.07% of Assenagon Asset Management's portfolio in Q2 2026, its #204 holding.
Assenagon Asset Management first reported a position in Tarsus Pharmaceuticals in Q2 2022 and has held it in 14 quarters since.
Assenagon Asset Management's Tarsus Pharmaceuticals position peaked at $92.3M in Q4 2025.
15 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.